Translational Oncology
Prof. Dr. Jens Siveke
Our overarching goal is to identify and individualize better diagnostic and therapeutic approaches for cancer patients. We aim to reduce the barriers and delays between bench work and patient needs. By combining suitable model systems (organoids, PDX, GEMM) with comprehensive profiling technologies and innovative therapeutics, we seek to identify targeting strategies that can be developed for clinical translation.
We have a laboratory focus on:
- comprehensive disease modeling and co-clinical trials
- multiomics with focus on spatiotemporal technologies
- drug discovery with focus on immune, epigenetic, metabolic and theranostic targeting
We perform biomarker-based and imaging studies for early detection of cancer and treatment response monitoring. We develop and perform early clinical proof-of-concept studies in solid cancers in combination with comprehensive translational molecular and imaging programs.
Future projects and goals
We aim to transfer and validate prioritized targets into more complex biological settings and generate preclinical data packages for clinical translation. Our focus is on intra- and intertumoral heterogeneity and the tumor microenvironment underlying phenotypical dynamics on multiple levels (response patterns, targets/pathways, cell-cell interactions, systemic factors).
We establish and develop further diagnostic and therapeutic platforms (in vivo/ex vivo models, organoids) for disease- and patient-relevant outcome evaluation of new targeting approaches (in collaboration with partners from academia and industry).
For clincial approaches we collaborate on deep and interoperable digital platforms (ecosystem) to accomplish complex cross-discipline approaches, next-level patient-reported experiences, and accelerated evaluation platforms for prioritized interventional approaches.
Prof. Dr. Jens Siveke
Abteilungsleiter - Partnerstandort Essen/Düsseldorf
Universitätsmedizin Essen West German Cancer Center
Translationale Onkologie